Physician profile
Anand Patel
NPI 1467445551
$11,285.90
in general payments reported to CMS, 2019-2025
34 companies · $2,328 in 2025
The $2,328 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $344 · 2021: $936 · 2022: $1,782 · 2023: $2,042 · 2024: $2,671 · 2025: $2,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,041.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,925.09 | 2019-2025 | |
| Janssen Biotech, INC. | $1,385.36 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,025.97 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $772.29 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $607.97 | 2022-2025 | Dupixent |
| Genzyme Corporation | $519.24 | 2022-2025 | |
| Gilead Sciences, INC. | $378.85 | 2019-2025 | |
| Qol Medical, LLC | $348.89 | 2023-2025 | Sucraid, Sucraid |
| Pfizer INC. | $328.21 | 2019-2025 | |
| Lilly USA, LLC | $289.50 | 2023-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $246.55 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $161.75 | 2019-2024 | Dificid |
| Apollo Endosurgery US INC | $145.20 | 2023 | Orbera Intragastric Balloon System |
| Phathom Pharmaceuticals, INC. | $118.08 | 2024-2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $113.11 | 2023-2024 | Givlaari |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $98.57 | 2019-2025 | |
| Celgene Corporation | $96.53 | 2021-2023 | Zeposia |
| Madrigal Pharmaceuticals | $90.17 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $88.78 | 2021-2022 | |
| Redhill Biopharma INC. | $84.37 | 2021 | |
| Ironwood Pharmaceuticals, INC | $79.95 | 2021-2024 | Linzess |
| Alexion Pharmaceuticals, INC. | $78.38 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $64.49 | 2024-2025 | Iqirvo |
| Shionogi INC | $50.20 | 2019-2020 | |
| Vivus LLC | $48.78 | 2022-2024 | Qsymia |
| Ardelyx, INC. | $35.86 | 2022-2023 | Ibsrela |
| Enterra Medical, INC. | $23.24 | 2023 | |
| Ethicon US, LLC | $16.35 | 2019 | |
| Amgen INC. | $16.05 | 2025 | Uplizna |
| Alfasigma USA, INC. | $12.67 | 2020 | |
| Daiichi Sankyo INC. | $12.02 | 2019 | |
| Olympus America INC. | $11.80 | 2019 | |
| Ucb, INC. | $11.63 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anand Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.